William Lewis Sells 3,009 Shares of Insmed (NASDAQ:INSM) Stock

Insmed, Inc. (NASDAQ:INSM) CEO William Lewis sold 3,009 shares of the stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $156.34, for a total transaction of $470,427.06. Following the transaction, the chief executive officer owned 303,882 shares of the company’s stock, valued at $47,508,911.88. The trade was a 0.98% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

William Lewis also recently made the following trade(s):

• On Tuesday, January 20th, William Lewis sold 10,699 shares of Insmed stock. The shares were sold at an average price of $158.93, for a total transaction of $1,700,392.07.
• On Monday, January 12th, William Lewis sold 19,215 shares of Insmed stock. The stock was sold at an average price of $169.00, for a total transaction of $3,247,335.00.
• On Thursday, January 8th, William Lewis sold 3,223 shares of Insmed stock. The stock was sold at an average price of $174.17, for a total transaction of $561,349.91.
• On Wednesday, January 7th, William Lewis sold 2,357 shares of Insmed stock. The shares were sold at an average price of $175.07, for a total value of $412,639.99.
• On Tuesday, January 6th, William Lewis sold 4,096 shares of Insmed stock. The stock was sold at an average price of $173.33, for a total value of $709,959.68.
• On Thursday, December 18th, William Lewis sold 10,699 shares of Insmed stock. The shares were sold at an average price of $166.97, for a total value of $1,786,412.03.

Insmed Stock Down 0.9%

NASDAQ:INSM opened at $151.03 on Friday. Insmed, Inc. has a twelve month low of $60.40 and a twelve month high of $212.75. The firm has a market capitalization of $32.21 billion, a price-to-earnings ratio of -24.40 and a beta of 1.11. The company has a quick ratio of 4.34, a current ratio of 4.63 and a debt-to-equity ratio of 0.59. The stock’s 50 day moving average price is $176.03 and its two-hundred day moving average price is $159.60.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in INSM. Gabelli Funds LLC boosted its position in shares of Insmed by 27.8% in the fourth quarter. Gabelli Funds LLC now owns 1,840 shares of the biopharmaceutical company’s stock valued at $320,000 after acquiring an additional 400 shares during the period. North Dakota State Investment Board bought a new position in Insmed during the fourth quarter worth about $1,141,000. Abacus Wealth Partners LLC bought a new stake in Insmed in the 4th quarter valued at about $418,000. iA Global Asset Management Inc. grew its position in shares of Insmed by 15,973.5% during the 4th quarter. iA Global Asset Management Inc. now owns 26,682 shares of the biopharmaceutical company’s stock worth $4,644,000 after purchasing an additional 26,516 shares in the last quarter. Finally, DNB Asset Management AS grew its position in shares of Insmed by 1,104.9% during the 4th quarter. DNB Asset Management AS now owns 40,918 shares of the biopharmaceutical company’s stock worth $7,121,000 after purchasing an additional 37,522 shares in the last quarter.

Analysts Set New Price Targets

A number of research firms recently commented on INSM. Leerink Partners reiterated an “outperform” rating on shares of Insmed in a report on Thursday, December 18th. Truist Financial set a $205.00 price objective on Insmed in a research report on Monday, January 12th. Wolfe Research set a $167.00 target price on Insmed and gave the stock an “outperform” rating in a research note on Thursday, December 18th. Cantor Fitzgerald increased their price target on Insmed from $216.00 to $230.00 and gave the company an “overweight” rating in a research note on Tuesday, December 16th. Finally, Royal Bank Of Canada raised their price target on Insmed from $197.00 to $200.00 and gave the company an “outperform” rating in a report on Wednesday, January 21st. Three research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $206.04.

Trending Headlines about Insmed

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: Large institutional holders remain significant and have been increasing positions, which supports structural demand and can limit downside. MarketBeat Institutional Holdings
• Positive Sentiment: Analyst coverage is strongly skewed to Buy/Strong Buy with an average price target well above the current trading level, implying upside if upcoming results and guidance meet expectations. MarketBeat Analyst Coverage
• Neutral Sentiment: Insmed set its Q4 and full‑year 2025 results release and conference call for Feb. 19 — a concrete near‑term catalyst that will provide revenue, margin and guidance data investors will use to re‑rate the stock. PR Newswire: Earnings Date
• Negative Sentiment: Clustered insider sales: multiple senior executives (CEO William Lewis, CFO Sara Bonstein, COO Roger Adsett and another officer) sold shares on Feb. 3. Such concentrated selling by leadership can be interpreted negatively and likely contributed to intraday weakness. InsiderTrades: Insider Sales
• Negative Sentiment: Pattern risk: the CFO and other officers had earlier sales in January, creating a sequence of executive trims this quarter rather than isolated trades; that pattern may increase short‑term selling pressure or investor caution ahead of Feb. 19. SEC Form 4 (CEO/CFO Sales)

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.